Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation

Myelodysplastic Syndromes Clinical Trial

Official title:

Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05968963
• Other study ID #: 20230726
• Secondary ID: 1R61CA263335-01A
• Status: Recruiting
• Phase: N/A
• Start date: November 28, 2023
• Est. completion date: August 1, 2024

Study information

• Verified date: November 2023
• Source: University of Miami
• Contact: Frank J Penedo, PhD
• Phone: (305) 284-4290
• Email: fpenedo[@]miami.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age

• have a primary diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or non Hodgkin's Lymphoma (NHL)

• have a treatment plan for an allogeneic hematopoietic stem cell transplant

• Speak English or Spanish

Exclusion Criteria:

• history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)

• severe cognitive impairment (per the short portable mental status questionnaire)

• hearing impairment

• active alcohol or substance dependence within the past six months

• participated in music therapy or mindfulness programs in the past six months

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Lymphoma
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Stem Cell Transplantation

Intervention

Behavioral:
• Mindfulness-based Music Therapy (MBMT)
Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
• Mindfulness Meditation (MM)
Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Miami	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Count of Participants Recruited	Recruitment will be measured by the count of participants successfully recruited and randomized into the study.	Baseline (T1)
Primary	Number of Participants Retained	Participant retention will be examined via the number of participants retained in the study.	Up to 18 months
Primary	Mean Number of Intervention Sessions that Participants Completed	Participant engagement will be examined via the mean number of intervention sessions completed by participants measured after the 8th (and last) intervention session which is given between 75 and 100 days post-transplant.	Up to 100 days post-transplant
Primary	Satisfaction Scores as Measured by Weekly Rating Satisfaction Score	Scores per item range from 0 to 5. Higher scores indicate more satisfaction.	Up to 100 days post-transplant
Secondary	Change in Health Related Quality of Life Scores as Measures by Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)	FACT-BMT score range 0-164, with higher scores indicating better quality of life.	Baseline (T1), up to 18 months
Secondary	Change in Pain as Measured by patient reported outcome measures (PROMIS®) pain scale.	(PROMIS®) pain scale is scored on a range of 3 to 15 with higher scores indicating higher pain.	Baseline (T1), up to 18 months
Secondary	Change in Fatigue as Measured by patient reported outcome measures (PROMIS®) Fatigue scale.	(PROMIS®) Fatigue scale is scored on a range of 8 to 40. Higher scores indicate higher fatigue.	Baseline (T1), up to 18 months
Secondary	Change in Cognitive Function Scores as Measured by The Repeatable Battery for the Assessment of Neuropsychological Status.	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores range from 40-160 with higher scores indicating better cognitive function.	Baseline (T1), up to 18 months
Secondary	Change in Sleep Quality Scores as Measured by Pittsburgh Sleep Quality Index	Pittsburgh Sleep Quality Index score range from 0 to 21. Higher score indicate worse sleep quality.	Baseline (T1), up to 18 months
Secondary	Number of Days to Engraftment Measured from Infusion to Engraftment.	To measure the number of days to engraftment we will extract from the electronic medical record (EMR) days from infusion to engraftment.	Up to 18 months
Secondary	Number of Days of Hospitalization Measured from Admission to Engraftment.	To measure the number of days of hospitalization we will extract from the electronic medical record (EMR) days of hospitalization from admission to engraftment.	Up to 18 months
Secondary	Number of Hospital Readmissions after Hospital Discharge	To measure the number of hospital readmissions we will extract from the electronic medical record (EMR) the number of hospital readmissions from hospital discharge.	Up to 100 days
Secondary	Number of Infections from Hospital Admission	To measure the number of infections we will extract from the electronic medical record (EMR) the number of infections from hospital admission measure up to 100 days post infusion.	up to 100 Days Post-Infusion Day
Secondary	Change in anxiety Scores as Measured with the Generalized anxiety disorder (GAD-7)	Generalized anxiety disorder (GAD-7) range is 0 to 21; higher score is associated with more severe anxiety.	Baseline (T1), up to 18 months
Secondary	Changes in Depression Scores as measured with the patient health questionnaire (PHQ-9)	PHQ-9 (patient health questionnaire) score range is from 0 to 27; higher score is associated with more severe depression.	Baseline (T1), up to 18 months
Secondary	Change in Cancer-specific Distress Scores as Measured by the Impact of Events Scale-Revised	Impact of Events Scale-Revised range is 0 to 88; higher score is associated with more effect caused by events.	Baseline (T1), up to 18 months
Secondary	Change in Serum Cortisol as Measured by ELISA	Serum cortisol levels are measured via ELISA. Serum Cortisol normal levels morning range: 10-20 mcg/dL ; afternoon range: 3-10 mcg/dL. Any values outside of the range are associated with higher stress and inflammation	Baseline (T1), up to 18 months
Secondary	Change in Immunocompetence as Measured by Cytokines	Cytokines levels are measured in pg/mL. Any values outside of the normal range are associated with inflammation	Baseline (T1), up to 18 months
Secondary	Change in Immunocompetence as Measured by Thymic Function	Thymic function T-cell receptor excision circles (TRECs) measured by TRECs/microliter.	Baseline (T1), up to 18 months
Secondary	Change in Immunocompetence as Measured by Regulatory T cells	Regulatory T cells measured as cells/mm^3	Baseline (T1), up to 18 months